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Significance statement: 
 
The thiazide-sensitive NaCl cotransporter (NCC) in the distal convoluted tubule (DCT) 
is critical for the renal control of ion homeostasis and blood pressure. NCC 
phosphorylation, and hence activity, is increased by cAMP-elevating stimuli, including 
β-adrenergic agonists and PTH. We tested the hypothesis that the inhibitor 1 (I1) of 
protein phosphatase 1 (PP1) mediates the effects of cAMP-elevating hormones on 
NCC. Using several in vitro and ex vivo approaches, we propose a novel signaling 
pathway in which a PKA-dependent phosphorylation of I1 inhibits the PP1-dependent 
dephosphorylation of NCC. This novel pathway may contribute to the physiological 
regulation of NCC and the development of arterial hypertension in the context of 
abnormal hormonal stimulation.  
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Abstract 
Background: The NaCl cotransporter (NCC) in the distal convoluted tubule (DCT) is 
critical for renal Na+ reabsorption and blood pressure control. A number of cAMP-
elevating hormones stimulate NCC phosphorylation, and hence activity.  
Methods: Using a variety of experiments on mouse ex vivo kidney preparations, we 
tested the hypothesis that the DCT-enriched protein phosphatase 1 inhibitor 1 (I1) 
mediates the effects of cAMP on NCC.  
Results: Treatment of isolated DCTs with forskolin and IBMX increased the 
phosphorylation of NCC via a protein kinase A (PKA)-dependent pathway. Likewise, 
ex vivo incubation of mouse kidney slices with isoproterenol, norepinephrine and PTH 
increased NCC phosphorylation. The cAMP-induced stimulation of NCC 
phosphorylation strongly correlated with the phosphorylation of I1 at its PKA 
consensus site (T35). Yeast two-hybrid and co-immunoprecipitation experiments in 
NCC-expressing MDCK cells indicated an interaction between NCC and the I1-target 
PP1. Moreover, PP1 dephosphorylated NCC in vitro and the PP1 inhibitor calyculin A 
increased NCC phosphorylation. Studies on kidney slices and isolated perfused 
kidneys of control and I1-KO mice demonstrated that I1 participates to the cAMP-
induced stimulation of NCC.  
Conclusion: Our data suggests a complete signal transduction pathway by which 
cAMP increases NCC phosphorylation via a PKA-dependent phosphorylation of I1 and 
subsequent inhibition of PP1. This pathway might be relevant for the physiological 
regulation or renal Na+ handling by cAMP-elevating hormones and may contribute to 
salt-sensitive hypertension in patients with endocrine disorders or sympathetic 
hyperactivity.   
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Introduction 
The thiazide-sensitive NaCl cotransporter (NCC) in the renal distal convoluted tubule 
(DCT) is crucial for the fine-tuning of renal sodium (Na+) reabsorption and hence for 
the control of blood pressure. NCC and the DCT are also critically involved in the renal 
control of potassium (K+), magnesium (Mg2+), calcium (Ca2+) and acid/base 
homeostasis1. The crucial role of NCC is evidenced by genetic diseases in which loss 
of function mutations of NCC cause Gitelman syndrome featuring hypokalemic 
alkalosis, hypomagnesemia, hypocalciuria and lowered arterial blood pressure2. 
Conversely, enhanced NCC activity due to mutations in its regulating kinases, namely 
the with no lysine (K) (WNK) WNK1 and WNK4, cause Familial Hyperkalemic 
Hypertension (FHH) with hypermagnesemia and hypercalciuria3. Moreover, mutations 
in ubiquitin-ligase complex proteins such as kelch-like-3 (KLHL3) and cullin-3 (CUL3), 
which control WNK4 stability, are also causative of FHH4,5. The WNK kinases control 
NCC activity via the STE20/SPS 1 -related Proline- and Alanine-rich Kinase (SPAK) 
and the Oxidative Stress-Response kinase 1 (OSR1). SPAK and OSR1 directly 
phosphorylate NCC at several serine and threonine residues located within the N-
terminal tail of the cotransporter6,7.  
The activity of the WNK-SPAK kinase pathway and NCC is regulated by various 
factors including the renin-angiotensin-aldosterone (RAAS) system8. Although the 
DCT expresses the cognate receptors for angiotensin II and aldosterone, recent work 
suggests that the effect of these hormones on NCC is indirectly mediated via changes 
in plasma K+ concentration ([K+])9,10. Plasma [K+] is proposed to modulate WNK4 
activity through changes in DCT membrane voltage and intracellular Cl- 
concentration11. Other NCC stimulators such as the β-adrenergic agonist isoproterenol 
as well as the parathyroid hormone (PTH) are thought to mediate their effects via 
intracellular cAMP12–14. Recently, the cAMP-dependent protein kinase (PKA) was 
implicated in the regulation of WNK4, suggesting that cAMP may also act via the 
WNK/SPAK kinase pathway13. However, these studies were mainly performed in 
heterologous expression systems and it remained unclear whether this and/or 
additional pathways contribute to the cAMP-dependent regulation of NCC in the native 
DCT. Some studies suggested that the kinase OSR1 and the extracellular signal-
regulated kinase (ERK)1/2 mitogen-activated protein kinase (MAPK) are also involved 
in the activation of NCC by catecholamines15 and PTH16, respectively.   
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Despite the progress on the elucidation of the role and regulation of the 
WNK/SPAK/OSR1 kinase pathway, little is known about the phosphatases that 
counterbalance the action of these kinases. As yet, three protein phosphatases (PP) 
were suggested to modulate NCC phosphorylation; PP1, PP3 (calcineurin) and PP4. 
In Xenopus laevis oocytes, heterologous co-expression of NCC with PP4 lowered 
NCC phosphorylation17. Likewise, pharmacological inhibition of PP1 with calyculin A 
18 and of PP3 with tacrolimus19,20 increased NCC phosphorylation in various 
experimental settings. The stimulatory effect of PP3 inhibition on NCC may have 
important clinical implications. In fact, a common side effect of calcineurin-inhibitor 
treatment is renal sodium retention and arterial hypertension, which correlates with an 
enhanced urinary excretion of phosphorylated NCC18,21. Nevertheless, the 
physiological role of the different phosphatases in the DCT and of the underlying 
mechanism regulating their function are unclear.   
Interestingly, both the catalytic activity and the substrate-speciﬁcity of phosphatases 
are often modulated by the interaction with speciﬁc regulatory subunits. We recently 
found that the endogenous inhibitor 1 (I1) of protein phosphatase 1 is highly expressed 
in the DCT with strong effects on NCC phosphorylation and arterial blood pressure22. 
I1 is a small 171 amino acid cytosolic protein encoded by the Ppp1r1a gene23. It is 
expressed in many organs including the brain, skeletal muscle, and the heart, where 
it is thought to contribute to neuronal plasticity24, muscle glycogen metabolism 25, and 
cardiac contractility and excitability23,26. Moreover, I1 was implicated in the control of 
the activity of the Na-K-ATPase in the heart27, while PP1 was found to modulate the 
inhibitory effect of WNK4 on  ROMK in the kidney28. Protein kinase A (PKA) 
phosphorylates I1 at a threonine residue in position 35 (T35), which activates I1 and 
makes it a strong and very specific inhibitor of PP1 with an IC50 value of 1nM29. 
Dephosphorylation of Thr35 by phosphatases such as PP2A and calcineurin (PP3) 
terminate the inhibitory action of I126. Interestingly, I1 is critically involved in β-
adrenergic and cAMP-dependent signaling in skeletal and heart muscle23,26 and I1 
deficient mice are partially protected from isoprenaline induced cardiac remodeling 
and arrhythmia30. 
Here, we tested the hypothesis that I1 is also critically involved in the cAMP/PKA-
dependent stimulation of NCC phosphorylation. Using a variety of ex vivo approaches, 
we propose a novel signal transduction pathway in which cAMP-dependent 
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phosphorylation and activation of I1 mediates the effect of cAMP-elevating hormones 
on NCC phosphorylation and hence activity.   
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Materials and Methods 
Reagents, cells and antibodies 
Unless otherwise stated, reagents were purchased from Sigma Aldrich (Buchs, 
Switzerland). Calyculin A was purchased from Cell Signaling Technologies 
(Massachusetts, USA). 8-Br-cAMP, PKI 14-22 amide, myristoylated and H-89 were 
purchased from Tocris Bioscience (Bristol, UK). Endothall was purchased from EMD 
Millipore (Billerica, MA, USA).  
tNCC, pT53NCC, pT58NCC and pS71NCC antibodies were previously 
described21,22,31. I1 antibody was purchased from Epitomics (California, USA. Cat. No: 
1747-1). The phosphosite-specific antibody recognizing pT35I1 was obtained via 
affinity purification of serum from rabbits immunized with the phospho-peptide NH2-
CRRRP(pT)PATL-CONH2 corresponding to mouse I1 (Pineda, Berlin, Germany). The 
specificity of the antibody was confirmed by immunohistochemistry (supplementary 
Fig 1). β-actin antibody was purchased from Sigma (Buchs, Cat. No: A5316 
Switzerland). Rabbit anti FLAG Antibody was purchased from GenScript (New Jersey, 
USA, Cat No: A01868). Rabbit anti AQP1 antibody was previously described32. tNCC 
and pT58NCC antibodies used to detect calyculin A and endothall  stimulation of NCC 
in MDCK type I cells were previously described (references 33 and 34 respectively). 
PP1c antibody was purchased from Abcam (Cambridge, UK, Cat No: 53315). 
Phospho-PKA substrate antibody was purchased from Cell Signaling Technologies 
(Massachusetts, USA, Cat. No: 9624). OSR1 antibody was purchased from Abcam 
(Cambridge, UK, Cat. No: 125468). 
MDCK type I cells with tetracycline inducible FLAG-tagged NCC were previously 
characterized35. 
Animals 
All animal experiments were conducted according to Swiss Laws and approved by the 
veterinary administration of the Canton of Zurich, Switzerland (License numbers: 
213/2015, and 185/2017). Experiments were conducted in male and female I1 
deficient mice (I1-KO)24 or wildtype (WT). For automated DCT isolation, mice 
expressing the enhanced green fluorescent protein (EGFP) in the early segment of 
the DCT (DCT1) under the parvalbumin promoter (PV-EGFP) were used22. Both 
transgenic lines and WT animals were kept in a homogenetic C57Bl/6 background. 
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Mice were maintained in a 12/12 h light/dark cycle and had access to standard chow 
type 3430 purchased from Provimi-Kliba (Kaiseraugst, Switzerland) and water ad 
libitum. Animals were age, weight and sex matched for each experimental series. 
Kidney slices  
Sex, age, and weight matched mice were used for the preparation of kidney slices as 
described previously18. To avoid confounding effects on NCC phosphorylation due to 
unequal dietary intake of K+, all mice were food deprived 16 hours prior to the 
experiment. 280 μm thick slices were incubated in Ringer-type solution for 30 minutes 
at 30,5°C for equilibration. The K+ concentration of the buffer was always 3 mmol/L. 
Stock solutions of isoproterenol, 3-isobutyl-1-methylxanthine (IBMX), calyculin A, PKI 
14-22 amide, myristoylated, and forskolin were prepared in DMSO. Stock solutions of 
8-Bromo-cAMP, Na+ salt, parathyroid hormone (PTH), norepinephrine (NE), and H-89 
were prepared in H2O. Equal volumes of either DMSO or H2O were added as control 
vehicle when needed. After 30 minutes incubation with the drugs or vehicle solutions, 
slices were snap frozen in liquid nitrogen or immersion fixed with 3% PFA and 
processed for immunoblotting and histology, respectively. Electron microscopy 
confirmed that the structural integrity of DCT cells was preserved under the ex vivo 
incubation of the tissue slices (supplementary Fig 2). Further experimental details can 
be found in the supplementary material and elsewhere18.  
Immunoblotting  
Immunoblotting was performed as previously described18. 
Statistics  
Unpaired Student’s t-test was used to compare two groups. For multiple comparison, 
one-way or two-way ANOVA followed by Tukey’s multiple comparison post-test was 
performed. 
Experimental details of the following methods: yeast two hybrid, immunoprecipitation, 
immunofluorescence staining and fluorescence quantification, isolated perfused 
mouse kidney, electron microscopy and automated DCT isolation are included as 
supplementary material of this manuscript.  
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Results 
cAMP-dependent stimulation of NCC phosphorylation is mediated by PKA  
First, we investigated whether an increase in intracellular cAMP levels stimulates NCC 
phosphorylation in native DCTs via a PKA-dependent pathway. We isolated EGFP-
positive early DCT fragments (DCT1) from transgenic mice expressing EGFP under 
the control of the parvalbumin promoter (PV-EGFP)22. The isolated DCTs were 
incubated with a cocktail of the adenylate cyclase stimulator forskolin (FSK) (10 
µmol/L) and the phosphodiesterase inhibitor IBMX (100 µmol/L) in the presence or 
absence of the PKA inhibitor PKI 14-22. Stimulation with FSK and IBMX triggered a 
significant increase in the phosphorylation of NCC accompanied with a mild increase 
in pSPAK-pOSR1 and a marked activation of PKA as monitored using a phospho-PKA 
substrate antibody (Fig 1).  NCC phosphorylation and the anti-phospho-PKA substrate 
signal substantially diminished upon co-incubation with the PKA inhibitor PKI 14-22 (1 
µmol/L). Under these conditions, the phosphorylation of SPAK and OSR1 remained 
almost unchanged compared to FSK/IBMX stimulation alone. Incubation of DCTs with 
10 µM PKI 14-22 abolished the phosphorylation of NCC and of the SPAK-OSR1 
kinases, indicating an overinhibition of the kinase pathway. Similar to PKI 14-22, the 
PKA inhibitor (H89) blocked the stimulatory effect of FSK/IBMX on NCC 
phosphorylation. Surprisingly and for unclear reasons, the effect of H89 was even 
more pronounced in cAMP-stimulated DCTs than in unstimulated DCTs 
(supplementary Fig 3).  
Genetic ablation of I1 attenuates the cAMP-dependent stimulation of NCC 
phosphorylation  
PKA phosphorylates I1 at position T35 in vitro, which renders I1 a potent and highly 
selective PP1 inhibitor29,36. To test whether I1 is critical for the cAMP-dependent 
stimulation of NCC, we analyzed kidney slices from WT and I1 deficient mice (I1-KO). 
Slices were incubated with either FSK, IBMX or the PKA-specific activator 8-Br-cAMP. 
All agonists strongly increased NCC phosphorylation at Thr 53 (Fig 2 A-C) and at Thr 
58 and Ser 71 (Supplementary Fig 4) in kidney slices from WT mice. In contrast, FSK, 
IBMX, and 8-Br-cAMP had only a small effect on NCC phosphorylation in kidney slices 
from I1-KO mice (Fig. 2 A-C, and supplementary Fig 4). 
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Protein phosphatase 1 interacts with and dephosphorylates NCC 
Previous studies by us and others showed that all isoforms of the catalytic subunit of 
PP1 (Ppp1ca, Ppp1cb and Ppp1cc) are highly expressed in mouse22 and rat37 DCTs. 
Using a yeast-two-hybrid screen on a mouse total kidney library, we found that a NCC 
fragment comprising the first 133 amino acids of rat NCC interacts with PP1 (Ppp1cb, 
GI number 161484667) in addition to other known interacting partners (e.g. OSR138, 
SPAK39 and Hsp4040). To further confirm that PP1 interacts with NCC, co-
immunoprecipitation experiments were performed using lysates from MDCK type I 
cells stably transfected with a tetracycline-inducible FLAG-tagged NCC35. As shown 
in figure 3A, endogenous PP1 was detected in samples immunoprecipitated with an 
anti-FLAG antibody but not in samples immunoprecipitated with an anti-AQP1 
antibody or in the absence of antibody. Moreover, in vitro experiments showed that 
the PP1 catalytic subunit α is able to dephosphorylate a synthetic peptide 
corresponding to the N-terminal tail of mouse NCC with a phosphorylated threonine at 
the position T58 (Fig 3B). 
To confirm the functional relevance of PP1 for the regulation of NCC, NCC-expressing 
MDCK cells were also treated with PP1 and PP2A inhibitors. While the inhibition of 
PP1 with calyculin A profoundly stimulated NCC phosphorylation, the specific 
inhibition of PP2A with endothall did not change the phosphorylation of NCC (Fig 3C). 
Likewise, calyculin A increased NCC phosphorylation in kidney slices from both WT 
and I1-KO mice to the same extent (Fig 3D), indicating that the effect of calyculin A is 
downstream of the regulatory action of I1.  
Norepinephrin and PTH stimulate NCC phosphorylation in a dose- and I1- 
dependent manner   
It has been previously proposed that norepinephrine (NE) stimulates the 
phosphorylation of NCC via a PKA-dependent mechanism41. Moreover, parathyroid 
hormone (PTH) was shown to activate the adenylate cyclase in the human and rat 
DCT promoting a strong increase in intracellular cAMP12,42.  Using kidney slices from 
WT and I1-KO mice, we tested whether these two hormones directly stimulate the 
phosphorylation of NCC in native DCTs and whether this effect depends on I1. As 
shown in figure 4 A and B, both hormones promote a dose-dependent increase in the 
phosphorylation of NCC in kidney slices from WT animals. The effect of NE on NCC 
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phosphorylation was completely abolished in I1-KO mice (Fig 4A). On the other hand, 
PTH still triggered a residual phosphorylation of NCC in kidney slices from I1-KO 
animals, although substantially weaker than in WT slices (Fig 4B).    
The β-adrenergic stimulation of NCC phosphorylation is mediated by I1 
Terker and coworkers suggested that β-adrenergic receptors are instrumental for the 
stimulation of NCC phosphorylation by catecholamines15.  We hypothesized that the 
β-adrenergic stimulation of NCC phosphorylation is mediated via I1. To test this 
hypothesis, kidney slices from WT and I1-KO mice were incubated with the β-
adrenergic agonist isoproterenol. Isoproterenol caused a significant rise in NCC 
phosphorylation in kidney slices from WT mice (Fig 5A) in agreement with previous 
observations by us18 and others15. However, this stimulatory effect was blunted in 
kidney slices from I1-KO mice, confirming the results with NE stimulation. Similar 
results were obtained using another ex-vivo model, namely the isolated perfused 
mouse kidney (Fig 5B).  
Surprisingly, we did not observe any significant increase in the phosphorylation of 
SPAK-OSR1 upon stimulation with isoproterenol (Fig 5A). Moreover, when SPAK 
phosphorylation and activity was clamped at high levels by incubating the kidney slices 
in a low Cl- solution (5 mmol/L)18, the stimulatory effect of isoproterenol on NCC was 
preserved and clearly additive to the effect of low Cl- (supplementary figure 5). 
Moreover, neither the expression of SPAK (Fig 5A) nor of OSR1 (Supplementary 
figure 6) show any difference between WT and I1-KO kidneys. These findings suggest 
that at least in our experimental settings, the β-adrenergic stimulation of NCC is largely 
independent from an activation of the WNK/SPAK-OSR1 pathway.     
cAMP promotes I1 phosphorylation at threonine 35 (T35) in native DCTs 
To assess whether the activation of PKA promotes I1 phosphorylation in native DCTs, 
we developed a phosphoform-specific antibody against the PKA-phosphorylation site. 
This new pT35-I1 antibody recognizes specifically the phosphorylated form of I1 as 
demonstrated by peptide competition experiments in immunofluorescent studies 
(supplementary figure 1). Unfortunately, the antibody works only for 
immunofluorescent studies. Therefore, we assessed the phosphorylation levels of I1 
by immunohistochemistry. Consecutive cryosections obtained from kidney slices 
incubated ex vivo either with vehicle or isoproterenol were stained with antibodies 
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against total I1 (tI1), pT35I1, tNCC and pT53NCC (Fig 6) and the staining intensities 
in DCTs were then quantified using ImageJ software as described in the material and 
method section. As previously reported22, I1 protein was found to be highly abundant 
in DCTs and in thick ascending limbs of Henle’s loop (TAL) (Fig 6A). In contrast to 
total I1, pT35I1 was barely detectable in DCTs in vehicle treated kidney slices. 
However, the signal for pT35I1 and also pT53NCC significantly increased in DCTs in 
kidney slices stimulated with isoproterenol (Fig 6A and B). Strikingly, the 
phosphorylation of I1 and NCC showed a strong linear correlation (Fig 6B). Of notice, 
both the total and the phosphorylated form of I1 were mainly seen at the apical cell 
surface of DCTs and hence in proximity to NCC (Fig 6A and C).    
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Discussion 
The DCT is the target for several cAMP-elevating hormones including β-adrenergic 
agonists, PTH and vasopressin12. These hormones are known to activate the DCT-
specific NaCl cotransporter NCC but the involved signal transduction pathways 
remained poorly defined. In the present study, we used a set of ex vivo approaches to 
reveal a complete signal transduction pathway by which cAMP-elevating hormones, 
via PKA, I1 and PP1 control NCC phosphorylation and hence activity.  
In our studies, we tested the effect of two physiologically relevant hormones, namely 
norepinephrine and PTH. Both hormones strongly stimulated NCC phosphorylation in 
a dose-dependent manner in a range from 0.1 nmol/L to 100 nmol/L. For 
norepinephrine, this range matches well with the reference range of normal plasma 
norepinephrine concentrations in humans (i.e. 0.83-10 nmol/L)43. For PTH, this range 
is above physiological levels (20-65 ng/L, ~2-6.5 pmol/L)44. However, the PTH applied 
to native tissue elicited effects on NCC already at concentrations that were far below 
those reported in the literature (100 nmol/L) to activate NCC and TRPV516,45 and to 
downregulate NaPi2a46 in cell systems and tissue slices, respectively. It is also 
important to consider that PTH is a peptide hormone that likely penetrates less 
efficiently into the tissue slices than the much smaller catecholamines. Moreover, the 
high levels of peptidases in the kidney slices (e.g. in the brush border of proximal 
tubules) may rapidly degrade PTH to inactive metabolites. Independent, from these 
possible technical hurdles, the data clearly indicate that both hormones are able to 
elicit a graded response of NCC phosphorylation. At least for norepinephrine, this 
graded response occurs in the range of physiological and pathophysiological plasma 
norepinephrine variations and may hence contribute to altered renal sodium 
reabsorption in response to changed sympathetic tone.  
Several studies already suggested that cAMP-dependent activation of PKA 
contributes to the hormonal regulation of NCC13,15,41,47–49. Nevertheless, as pointed out 
by Mutig et al. direct experimental support for the role of cAMP and PKA for the control 
of NCC activity in native DCTs had been limited probably due to the difficulty to 
establish readily available and suitable DCT cell models48. Now, using isolated mouse 
DCTs and kidney slices incubated ex vivo with forskolin and IBMX in the absence or 
presence of the PKA inhibitors PKI 14-22 and H-89, we provide compelling evidence 
that cAMP and PKA modify NCC activity in the native DCT. I1 is a direct target for PKA, 
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which phosphorylates I1 at a threonine in position 53 (pT35I1) and converts it into a 
potent and selective inhibitor of PP129. Consistent with an activation of the cAMP/PKA 
pathway in native DCTs, we observed a profound stimulation of I1 phosphorylation at 
the consensus PKA site (pT35) in response to isoproterenol stimulation. The I1 
phosphorylation strongly correlated with the level of NCC phosphorylation suggesting 
that they are functionally linked. Interestingly, I1 appears to be barely phosphorylated 
at the PKA site (T35) in DCTs of vehicle-treated kidney slices suggesting that I1-
dependent NCC regulation plays a significant role in response to hormonal stimuli but 
not under resting conditions. 
In vitro kinase assays and experiments in heterologous expression systems suggested 
that PKA exerts its effects on NCC via the classical KHL3-WNK4-SPAK pathway. 
PKA-mediated phosphorylation of KLH3 at S433 decreases KLH3-dependent 
ubiquitination and degradation of WNK447. Likewise, PKA phosphorylates WNK4 at 
multiple sites including S64 and S1169, which finally promotes WNK4-dependent 
phosphorylation and activation of SPAK13. PP1 was shown to modulate the 
phosphorylation levels of both WNK428 and SPAK50. Studies on the regulation of the 
Na-K-2Cl cotransporter NKCC1, which is structurally related to NCC, suggested that 
PP1 binds to the N-terminal tail of NKCC1 in direct proximity to SPAK to 
dephosphorylate both SPAK and NKCC150. NCC lacks the amino acid motif mediating 
the binding of PP1 to NKCC150. Nevertheless, our yeast-two-hybrid and co-
immunoprecipitation data suggest that PP1 and NCC do also interact and might be 
linked in a signaling complex that may involve also WNK4 and SPAK/OSR1. Therefore, 
it is conceivable that I1 and PP1 may control NCC activity directly via NCC-
dephosphorylation and/or indirectly via controlling WNK4 and SPAK/OSR1 
phosphorylation. However, neither in the current nor in our previous studies, we 
observed significant evidence for an involvement of I1 in SPAK/OSR1 regulation. The 
abundance and subcellular localization of total-SPAK, total-OSR1 (this study) and 
pSPAK/pOSR1 were similar in the kidneys and DCTs of wildtype and I1-KO mice 22. 
Moreover, FSK/IBMX and isoproterenol had no significant effects on SPAK/OSR1 
phosphorylation in isolated DCTs (Fig 1) and in kidney slices (Fig 5), respectively. 
Likewise, incubation of the kidney slices in a low Cl--solution, which clamps 
SPAK/OSR1 activity at high levels18 did not block the stimulatory effect of isoproterenol 
on NCC phosphorylation (suppl. Fig 5). Nevertheless, these negative results do not 
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formally exclude some activation of the WNK4/SPAK/OSR1 pathway. In fact, we 
consistently observed slight, but never statistically significant, increases in 
pSPAK/OSR1 immunoreactivities in tissue samples treated with FSK/IBMX and 
isoproterenol. Moreover, previous studies on heterologous expression systems linked 
SPAK to the cAMP/PKA-dependent NCC regulation13, while studies on knockout 
mouse models implicated OSR1 (but not SPAK) in the catecholamine-dependent 
control of NCC15. Part of these discrepancies may reflect the different experimental 
settings (e.g. in vitro, ex vivo, in vivo) and compounds used, but they may also indicate 
some redundancies in the signaling pathways, by which cAMP-elevating hormones 
stimulate NCC activity. In line with this view, we consistently observed some residual 
cAMP-dependent stimulation of NCC phosphorylation in kidneys of I1-KO mice in 
response to forskolin/IBMX and in particular in response to PTH. In contrast, the effect 
of catecholamines (isoproterenol and norepinephrine) on NCC phosphorylation 
appeared to depend almost exclusively on the presence of I1. A possible explanation 
for these differences might be a compartmentalization of the cAMP signaling pathways. 
In fact, cAMP reporter assays provided evidence for a spatial and temporal control of 
cAMP dynamics due to the presence of local micro-domains with proteins producing 
and degrading cAMP51, which allow circumscribed effects independent from cAMP 
levels outside these microdomains52. Thus, the hormone-induced cAMP/PKA-
dependent activation of NCC may involve several redundant pathways including the 
previously characterized WNK4, SPAK and OSR1 kinase pathways15,35,48,53. The 
current study adds I1 as an important additional regulator and suggests that in addition 
to the NCC-controlling kinases also the phosphatases are tightly regulated. Figure 7 
shows the proposed signaling model that we believe best explains the current 
observations in the context of prior knowledge.  
Aside from these novel insights into the molecular mechanism controlling NCC 
function, our findings may have some cIinical implications. Inappropriately high 
sympathetic activity is thought to contribute to cardiovascular diseases including 
cardiac arrhythmia, cardiac failure, and arterial hypertension54. Previous studies 
already implicated I1 in the β-adrenergic response of the heart modulating cardiac 
contractility55, excitibality22, and remodeling23. The present study extends these 
observations to the kidney and shows that I1 is also critically involved in the renal 
response to catecholamines. Our data indicate that catecholamines increase the 
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phosphorylation of I1 at the PKA-consensus site T35, which convert I1 into a potent 
inhibitor of PP1-dependent NCC dephosphorylation. This finally increases NCC 
phosphorylation as observed in the present and several other15,41,56 but not all57 
previous studies and may contribute to norepinephrine-induced salt sensitive 
hypertension 58. Interestingly, the pT35 site of I1 is dephosphorylated by PP3 
(calcineurin) 23. Immunosuppressive therapy with calcineurin inhibitors such as 
tacrolimus and cyclosporine A is often complicated by the development of arterial 
hypertension, which was suggested to be linked to renal Na+ retention due to an 
activation of NCC 19. It is tempting to speculate that at least part of these effects are 
also mediated via I1. Future in vivo studies, will have to address the relevance of renal 
I1 for catecholamine- and calcineurin-induced arterial hypertension.     
In summary, the present study identified the inhibitor 1 (I1) of protein phosphatase 1 
as a central regulatory element in the signal transduction cascade that mediates the 
stimulatory effects of cAMP on the thiazide-sensitive NaCl cotransporter. I1 may 
represent an interesting point of convergence for different kinase and phosphatase 
pathways in the DCT contributing to the regulation of NCC in health and disease. 
Given its relevance for both the cardiac and renal response to β-adrenergic stimulation, 
I1 might also be an interesting drug target for the treatment of cardiovascular diseases, 
including arterial hypertension. 
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Figure 1: PKA activation stimulates NCC phosphorylation in native DCTs. Left panel 
represents a typical immunoblot of isolated DCTs treated with vehicle, 10 µmol/L FSK 
+ 100 µmol/L IBMX, FSK / IBMX + 1 µmol/L PKI 14-22 and FSK / IBMX + 10 µmol/L 
PKI 14-22 . The activity of PKA was monitored using a phospho-PKA substrate 
antibody. Each lane corresponds to 400 DCT fragments. On the right, the 
densitometric analysis of pT53NCC/tNCC and pSPAK-pOSR1/tSPAK from 4 
independent experiments (”n” in brackets) normalized to control vehicle group (red 
line) is represented. Error bars represent the standard error of the mean (SEM). 
*p<0.05 compared to control vehicle condition and assessed by one-way ANOVA 
followed by Tukey's multiple comparisons test.  
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Figure 2: PKA stimulation of NCC phosphorylation is impaired in I1-KO mice. 
Representative immunoblots showing the effect of (A) IBMX (100 µmol/L), (B) forskolin 
(10 µmol/L) and (C) 8-Br-cAMP (10 µmol/L) on NCC phosphorylation at position T53 
in WT and I1-KO kidney slices. Bar charts represent the densitometric quantification 
of pT53NCC/tNCC normalized to control vehicle of each genotype from 6-9 slices (”n” 
in brackets) from 2-3 mice. Error bars represent the standard error of the mean (SEM). 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 assessed by two-way ANOVA followed 
by Tukey’s multiple comparison post-test. 
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Figure 3: Protein Phosphatase 1 interacts with NCC and dephosphorylates it. A: 
FLAG IP pull down of NCC (left) and the catalytic subunit of PP1 (PPIc) (right). 
Unrelated anti-AQP1 antibody as well as no antibody were used as negative control. 
B: in vitro dephosphorylation of biotinylated pT58-mNCC peptide by PP1. C: Changes 
in NCC phosphorylation at T58 in MDCK type I cells with tetracycline inducible FLAG-
tagged NCC expression upon treatment with calyculin A (left panel) or specific PP2A 
inhibitor endothall (right panel). Graph represents the densitometric quantification of 
immunoblots from 2 independent experiments *p<0.05 by one-way ANOVA followed 
by Tukey's multiple comparisons test. D: Changes in NCC phosphorylation upon 
treatment of WT and I1-KO mouse kidney slices with Calyculin A (20 nmol/L). Bar 
charts represent the densitometric quantification of pT53NCC/tNCC from 6 slices (in 
brackets) normalized to control vehicle of each genotype (2 mice per group). Error 
bars represent the standard error of the mean (SEM). ns: non-significant; ****p<0.0001 
assessed by two-way ANOVA followed by Tukey’s multiple comparison post-test. 
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Figure 4: I1 mediates the effect of cAMP-increasing hormones on NCC 
phosphorylation. Dose-response effect of (A) Norepinephrine (NE) and (B) 
parathyroid hormone (PTH) on NCC phosphorylation (T53) in WT and I1-KO mouse 
kidney slices.  Graphs represent the densitometric quantification of pT53NCC/tNCC 
normalized to control vehicle of each genotype (red line). The number of slices 
assayed from 1 (NE) or 2 (PTH) mice per genotype are in brackets. Error bars 
represent the standard error of the mean (SEM). Stars denote statistically significant 
differences (*p<0.05, **p<0.01, ****p<0.0001) between the two genotypes for the 
same hormone concentration assessed by unpaired Student’s t-test. 
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Figure 5: The β-adrenergic stimulation of NCC phosphorylation is impaired in 1-KO 
mice. A: Dose-response effect of β-adrenergic agonist isoproterenol on the 
phosphorylation of NCC (T53), SPAK and OSR1 in WT and I1-KO kidney slices. 
Graphs represent the densitometric quantification of the phosphorylation of 
pT53NCC/tNCC and pSPAK-pOSR1/tSPAK normalized to vehicle control of each 
genotype from 3-15 slices (in brackets) (1-5 mice), Stars represent statistical 
significance (*p<0.05, **p<0.01, ****p<0.0001) of the comparison between the two 
genotypes for the same concentration of isoproterenol assessed by unpaired 
Student’s t-test. B: β-adrenergic stimulation of NCC phosphorylation in isolated 
perfuse mouse kidneys. Bar charts represent the densitometric quantification of 
pT53NCC/tNCC normalized to control vehicle of each genotype in 4-5 mice / 
experiment (”n” in brackets). ns: non-significant; **p<0.01 assessed by two-way 
ANOVA followed by Tukey’s multiple comparison post-test. Error bars represent the 
standard error of the mean (SEM). 
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Figure 6: β-adrenergic stimulation promotes the phosphorylation of I1 at threonine 35 
in native DCTs. A: Representative immunofluorescence stainings of tI1, pT35I1, tNCC 
and pT53NCC in consecutive sections of kidney slices from WT mice are shown. 
Slices were treated with isoproterenol 100 nmol/L or vehicle (scale bar 25 µm). B: The 
graph represents the relative mean intensity of pT35I1 staining (left panel) or 
pT53NCC (middle panel) in 6-7 slices (in brackets) from 3 mice (see supplementary 
methods for details). Error bars represent the standard error of the mean (SEM). 
*p<0.05, **p<0.01 assessed by unpaired Student’s t-test. Right panel represents the 
linear correlation between I1 (pT35) and NCC (pT53) phosphorylation. C: Higher 
magnification of typical pT35I1 staining in kidney slices treated with vehicle (left panel) 
and isoproterenol (right panel) highlighting its marked apical accumulation.  (scale bar 
25 µm) 
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Figure 7: Model of the stimulation of NCC phosphorylation by cAMP-increasing 
hormones. The cAMP-dependent activation of the WNK/SPAK/OSR1 pathway was 
show in previous studies13,15,53. The cAMP-dependent activation of the I1/PP1 
pathway is presented in the current study.   
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Detailed methods 
Yeast two hybrid 
A yeast two hybrid (Y2H) screen was performed by Hybrigenics (Hybrigenics Services, 
S.A.S., Paris, France (http://www.hybrigenics-services.com)) on a mouse total kidney 
library with the first 133 amino acids of rat NCC as the bait fragment.  
Immunoprecipitation 
MDCK type I cells with tetracycline inducible FLAG-tagged NCC expression were 
grown until confluent on polyester supports and induced for 18 hrs with tetracycline 
(1µg/µl). Cells were lysed in 20 mm Tris, 150 mm NaCl, 1% Triton-X, 0.01% SDS, 
pH7.4, containing protease inhibitors Leupeptin and Pefabloc and phosphatase 
inhibitor mixture tablets (PhosSTOP, Roche Diagnostics). NCC was 
immunoprecipitated (IP) from the cleared lysate using a rabbit anti-FLAG antibody. 
Similar IPs without antibody or use of an AQP1 antibody served as a negative control.  
Immunofluorescence staining and quantification 
6-7 acute kidney slices (280 µm) from 3 mice (3 independent experiments) were 
prepared and incubated with isoproterenol 100 nmol/L or vehicle as described before. 
After stimulation, slices were fixed by immersion in 3% paraformaldehyde (PFA) 
prepared in 0.1 mol/L phosphate buffer (pH 7.4, 300 mOsm). After washing in similar 
buffer without PFA, whole slices were mounted on an organic support, frozen in liquid 
propane and sectioned (4 µm) to proceed with immunofluorescence staining as 
previously described 1. 
For the quantification of fluorescence intensity, at least two sets of 4 consecutive 
sections (4 µm) per slice (280 µm) were stained with the following primary antibodies 
tI1, pT35I1, tNCC and pT53NCC. The sections were imaged (1 image / 4 µm section) 
using a Leica SP8 inverse STED 3X confocal microscope equipped with a 20X multi-
immersion objective (HC PL APO CS2). Within each image, all DCTs that could be 
identified in all four consecutive sections were selected for quantification (4-15 DCTs 
/ image). The mean fluorescence intensity of the whole DCT was quantified using 
ImageJ and divided by the mean intensity of a non-stained area of the same image to 
correct for background differences. The intensities of all DCTs within one image were 
averaged to obtain one value per image per antibody. Similarly, the intensity of all 
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images coming from the same 280 µm slice stained with the same antibody were 
averaged to obtain one value per slice which is represented in figure 6. 
Isolated perfused mouse kidney  
Isolated mouse kidney perfusion was performed at 37°C in a small animal perfusion 
system (Hugo Sachs Elektronik, Germany) as previously described 2. To reduce the 
scattering of NCC activation between animals, the Renin-Angiotensin-Aldosterone 
System (RAAS) was suppressed 2 days prior to the experiment by feeding age and 
weight matched male WT and I1 deficient mice with 8% NaCl diet. In all experiments, 
kidneys were perfused for 40 minutes with control buffer before isoproterenol was 
added to a final concentration of 100 nmol/L. Kidneys were further perfused for another 
40 minutes and finally snap frozen in liquid nitrogen for western blot analysis.  
Electron Microscopy 
Kidney slices were cut with a vibratome as described before and incubated in control 
buffer for 0, 30 or 60 min. Afterwards, slices were fixed overnight in 3% PFA and 1% 
glutaraldehyde in 0.1 mol/L phosphate buffer pH 7.3, 300 mOsm. The slices were then 
rinsed in 0.1 mol/L phosphate buffer before post-fixation in 1% osmium tetroxide in 
phosphate buffer for 2h at room temperature. Following dehydration through a graded 
series of ethanol, the slices were infiltrated and embedded in Epoxy embedding 
medium (Fluka, Seelze, Germany) overnight at room temperature. Thin sections (70 
– 75 nm) were cut on a Leica EM FCS ultramicrotome and collected onto 100 mesh 
copper grids. Sections were stained with uranyl acetate 30 min and Reynold’s lead 
citrate 10 min. Grids were analyzed on a Philips CM 100 (Eindhoven, The 
Netherlands) at 80 kV. 
Automated DCT isolation 
To sort single renal DCT1 fragments, mice expressing EGFP under the control of the 
parvalbumin promoter (PV-EGFP) 3 were anesthetized with isoflurane (Attane, Piramal, 
India) and perfused through the heart first with 10 ml of cold PBS and then with 10 ml 
of digestion solution (1mg/ml collagenase (Worthington Biochemical Corporation, 
Lakewood, NJ08701, USA); 1mg/ml hyaluronidase and 0.1mg/ml DNaseI prepared in 
ice-cold KREBS (in mmol/L): 130 NaCl, 10 HEPES, 3 KCl, 1 NaH2PO4, 2.5 CaCl2, 1.8 
MgSO4, 10 glucose, pH 7.3). Renal cortex from both kidneys was dissected under a 
stereomicroscope. Samples were finely minced and digested in 20 ml of fresh 
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digestion solution at 30°C for 17 minutes. The tubular digest was first filtered through 
250- and 212-μm nylon sieves. The flow-through was then filtered with a 100-μm and 
a 40-μm cell strainer (Becton Dickinson Labware, Franklin Lakes, NJ). The tubules 
retained by the 40-μm cell strainer were diluted with ice-cold Krebs to a total volume 
of 50 ml. All sortings were performed with a large particle sorter (BioSorter) instrument 
(Union Biometrica, Somerville, MA). The following instrument settings were used: 
delay 10 mS, width 6.5 mS, PMT 350 volt, sample cup pressure 8.5 psi, pre-analysis 
chamber pressure 4.8-5.4 psi. The sample fluid pressure was set to maintain a sort 
frequency of 10-20 events/s. The mixer speed was 50%. Sorted tubules were collected 
directly into ice-cold KREBS and centrifuged at 800g for 4 minutes. 
After sorting, a suspension of 800 DCT fragments was treated with either vehicle 
(DMSO) or 10 µmol/L FSK + 100 µmol/L IBMX, or 20 µmol/L H-89  or 1-10 µmol/L of 
PKI 14-22 amide, myristoylated or a combination of FSK/IBMX plus one of the PKA 
inhibitors. Treatment lasted 20 min and was performed at room temperature. After 
treatment, samples were shortly centrifuged, the supernatant was removed and tubuli 
were resuspended in Laemli buffer and further processed for immunoblot as described 
elsewhere4. 
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Supplementary figure 1: Assessment of the specificity of the pT35I1 antibody by 
immunohistochemistry. A: Consecutive sections of kidneys from WT animals stained 
with pT35I1 antibody (left panel), the same antibody previously incubated with the 
phospho-peptide NH2-CRRRP(pT)PATL-CONH2 (middle panel) or pre-incubated with 
the dephospho-peptide NH2-CRRRPTPATL-CONH2 (right panel). B: Consecutive 
sections of kidneys from WT animals (upper panel of three images) or I1-KO mice 
(lower panel of three images) stained with NKCC2, NCC and pT35I1 antibodies.  
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Supplementary figure 2: Assessment of DCT integrity in kidney slices from WT 
mice immediately after slicing (left panel) or incubated in control solution during 30 min 
(middle panel) and 60 min (right panel). Scale bar 10 µm. 
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Supplementary figure 3: Inhibition of cAMP-dependent phosphorylation of NCC by 
the PKA inhibitor H-89. Left panel represents a typical immunoblot of isolated DCTs 
treated with 1) vehicle, 2) 10 µmol/L FSK + 100 µmol/L IBMX, 3) 20 µmol/L H-89 and 
4) FSK+IBMX+H-89 in the same concentrations previously used. Each lane 
corresponds to 400 DCT fragments. On the right panel, a densitometric analysis of the 
pT53NCC/tNCC from 5-8 independent experiments (”n” in brackets) normalized to 
control vehicle group (red line) is represented. *p<0.05 compared to control vehicle 
condition and assessed by one-way ANOVA followed by Tukey's multiple comparisons 
test. 
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Supplementary figure 4: Stimulation of NCC phosphorylation at T58 and S71 
with cAMP elevating agents. Representative immunoblots showing the effect of (A) 
IBMX (100 µmol/L), (B) forskolin (10 µmol/L) and (C) 8-Br-cAMP (10 µmol/L) on NCC 
phosphorylation at position T58 and S71 in WT and I1-KO kidney slices. The 
densitometric quantification of the immunoblots is available in supplementary table 1. 
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Supplementary figure 5: Effect of low Cl- on the stimulation of NCC and SPAK-
OSR1 phosphorylation by isoproterenol in kidney slices of WT mouse. Graph 
represents the densitometric analysis of the phosphorylation of NCC at T53 (left) or 
the 70 KDa band of pSPAK-pOSR1 immunoblot (right) normalized to control vehicle. 
* p<0.05, **p<0.01, ns: non-significant assessed by one-way ANOVA followed by 
Tukey's multiple comparisons test. n= 3 slices (in brackets) from 1 mouse. 
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Supplementary figure 6: Expression of OSR1 in WT and I1-KO mice. The 
graph represents the densitometric quantification of tOSR1/β-actin in all bands 
shown normalized to WT. 
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Supplementary table 1: Densitometric quantification of Supplementary Figure 4 
 
  
mean SEM n Two-way-ANOVA + Tukey's multiple comparisson adjusted p value
WT_vehicle_pT58NCC 1 0.094367 3 WT vehicle vs FSK <0.0001
WT_FSK_pT58NCC 2.499423 0.081614 3 I1-Ko vehicle vs FSK 0.0029
I-1_KO_vehicle_pT58NCC 1 0.070559 3 WT FSK vs I1-KO FSK 0.0051
I-1_KO_FSK_pT58NCC 1.784053 0.147475 3
WT_vehicle_pS71NCC 1 0.073505 3 WT vehicle vs FSK <0.0001
WT_FSK_pS71NCC 2.691473 0.169197 3 I1-KO vehicle vs FSK 0.006
I-1_KO_vehicle_pS71NCC 1 0.072473 3 WT FSK vs I1-KO FSK 0.0039
I-1_KO_FSK_pS71NCC 1.815317 0.136574 3
mean SEM n Two-way-ANOVA + Tukey's multiple comparisson adjusted p value
WT_vehicle_pT58NCC 1 0.083918 3 WT vehicle vs IBMX <0.0001
WT_IBMX_pT58NCC 2.290356 0.080265 3 I1-KO vehicle vs IBMX 0.1023
I-1_KO_vehicle_pT58NCC 1 0.047617 3 WT IBMX vs I1-KO IBMX <0.0001
I-1_KO_IBMX_pT58NCC 1.300646 0.095564 3
WT_vehicle_pS71NCC 1 0.159223 3 WT vehicle vs IBMX 0.0039
WT_IBMX_pS71NCC 1.936363 0.184994 3 I1-KO vehicle vs IBMX 0.1004
I-1_KO_vehicle_pS71NCC 1 0.068808 3 WT IBMX vs I1-KO IBMX 0.1493
I-1_KO_IBMX_pS71NCC 1.494105 0.047443 3
mean SEM n Two-way-ANOVA + Tukey's multiple comparisson adjusted p value
WT_vehicle_pT58NCC 0.991639 0.107951 3 WT vehicle vs 8-Br-cAMP 0.0008
WT_8-Br-cAMP_pT58NCC 1.970833 0.118414 3 I1-KO vehicle vs 8-Br-cAMP 0.9156
I-1_KO_vehicle_pT58NCC 1.051336 0.034929 3 WT 8-Br-cAMP vs I1-KO 8-Br-cAMP 0.0025
I-1_KO_8-Br-cAMP_pT58NCC 1.146948 0.132396 3
WT_vehicle_pS71NCC 1.272917 0.166387 3 WT vehicle vs 8-Br-cAMP 0.0008
WT_8-Br-cAMP_pS71NCC 2.193591 0.214361 3 I1-KO vehicle vs 8-Br-cAMP 0.9156
I-1_KO_vehicle_pS71NCC 1.506866 0.130078 3 WT 8-Br-cAMP vs I1-KO 8-Br-cAMP 0.0025
I-1_KO_8-Br-cAMP_pS71NCC 1.769712 0.217122 3
FSK stimulation
Summary
IBMX stimulation
8-Br-cAMP stimulation
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Supplementary table 2: Densitometric quantification of pT58NCC shown in figure 
3D of the main manuscript 
 
  
mean SEM n
pT58NCC wt vehicle 1.00 0.09 3
pT58NCC WT Calyc_A 2.01 0.20 3
pT58NCC I1-KO vehicle 1.00 0.13 3
pT58NCC I1-KO Calyc_A 2.18 0.42 3
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